Abstract
Cardiovascular disease is one of the most important risk factors for mortality and morbidity in patients with Chronic Kidney Disease (CKD). This systematic review focuses on the protective effects of diuretics against the development of cardiovascular disease in patients with CKD. Among various kinds of diuretics, spironolactone, a mineralocorticoid receptor antagonist, has been shown to have protective effects against cardiovascular disease in patients with all stages of CKD, including predialysis, hemodialysis, and peritoneal dialysis. Low-dose loop diuretics have also been shown to have cardioprotective effects in patients with CKD during the pre-dialysis and hemodialysis stages; however, high-dose loop diuretics have failed to show these cardioprotective effects. The protective effects of other classes of diuretics, including thiazide and tolvaptan, against cardiovascular diseases in patients with CKD remain unclear.
Keywords: Diuretics, cardiovascular disease, chronic kidney disease, spironolactone, mineralocorticoid receptor antagonist, dialysis.
Graphical Abstract
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Protective Effects of Diuretics Against the Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: A Systematic Review
Volume: 16 Issue: 1
Author(s): Akinori Aomatsu, Susumu Ookawara, Kenichi Ishibashi and Yoshiyuki Morishita*
Affiliation:
- Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama,Japan
Keywords: Diuretics, cardiovascular disease, chronic kidney disease, spironolactone, mineralocorticoid receptor antagonist, dialysis.
Abstract: Cardiovascular disease is one of the most important risk factors for mortality and morbidity in patients with Chronic Kidney Disease (CKD). This systematic review focuses on the protective effects of diuretics against the development of cardiovascular disease in patients with CKD. Among various kinds of diuretics, spironolactone, a mineralocorticoid receptor antagonist, has been shown to have protective effects against cardiovascular disease in patients with all stages of CKD, including predialysis, hemodialysis, and peritoneal dialysis. Low-dose loop diuretics have also been shown to have cardioprotective effects in patients with CKD during the pre-dialysis and hemodialysis stages; however, high-dose loop diuretics have failed to show these cardioprotective effects. The protective effects of other classes of diuretics, including thiazide and tolvaptan, against cardiovascular diseases in patients with CKD remain unclear.
Export Options
About this article
Cite this article as:
Aomatsu Akinori , Ookawara Susumu , Ishibashi Kenichi and Morishita Yoshiyuki*, Protective Effects of Diuretics Against the Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: A Systematic Review, Cardiovascular & Hematological Agents in Medicinal Chemistry 2018; 16 (1) . https://dx.doi.org/10.2174/1871525716666180402145228
DOI https://dx.doi.org/10.2174/1871525716666180402145228 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Uteroplacental Circulation and Fetal Vascular Function and Development
Current Vascular Pharmacology Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis
Current Pharmaceutical Biotechnology Incretin-Based Antidiabetic Agents for the Management of Non-Alcoholic Fatty Liver Disease
Current Vascular Pharmacology Angiotensin II Type I Receptor Blocker and Endothelial Function in Humans: Role of Nitric Oxide and Oxidative Stress
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Lipid Carriers for Gene Therapy
Current Drug Delivery Current Options for the Pharmacotherapy of Obesity
Current Pharmaceutical Design Polyphenols can Potentially Prevent Atherosclerosis and Cardiovascular Disease by Modulating Macrophage Cholesterol Metabolism
Current Molecular Pharmacology Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Editorial [Hot Topic: Cardiac Cell Therapy: anno 2011 (Executive Guest Editor: Sophie Van Linthout)
Current Pharmaceutical Design Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?
Current Vascular Pharmacology Social Media as a Means to Disseminate and Advocate Cardiovascular Research: Why, How, and Best Practices
Current Cardiology Reviews Autophagy and Mitochondria in Obesity and Type 2 Diabetes
Current Diabetes Reviews Barriers to Achieving Optimal Glycemic Control in a Multi-Ethnic Society: A US Focus
Current Diabetes Reviews Platelet SERT as a Peripheral Biomarker of Serotonergic Neurotransmission in the Central Nervous System
Current Medicinal Chemistry Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Analysis of Carotid Ultrasound Images for the Assessment of Stroke Risk Using Level Set Method
Current Medical Imaging An Update on Clinical Drug Interactions with the Herbal Antidepressant St. Johns wort
Current Drug Metabolism Lipid-lowering Therapy in the Diabetic Foot: Seeing the Whole Iceberg and not Just the Tip
Current Vascular Pharmacology GPER and ER: Estrogen Receptors with Distinct Biological Roles in Breast Cancer
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)